Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry

July 2009 in “ Drug Metabolism and Disposition ”

Anna Lundahl, Hans Lennernäs, Lars Knutson, Ulf Bondesson, Mikael Hedeland

finasteride metabolites glucuronidation high-performance liquid chromatography tandem mass spectrometry Propecia HPLC MS/MS

Studysummary This study identified previously unknown phase I and phase II metabolites of finasteride in human bile and urine using a specialized bile collection technique and advanced mass spectrometry analysis. Our plain-language summary of this paper — not a Tressless recommendation.

This document reports on the identification of finasteride metabolites in human bile and urine using high-performance liquid chromatography/tandem mass spectrometry. The study identified two novel metabolites of finasteride, MX and MY, in human bile and urine, and found that glucuronidation was the most important conjugation pathway for the finasteride phase I metabolites. The study provides new information about the metabolism of finasteride, which is important for understanding the safety and efficacy of the drug.

View this study on dmd.aspetjournals.org →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

The Effect of St. John's Wort on the Pharmacokinetics, Metabolism, and Biliary Excretion of Finasteride and Its Metabolites in Healthy Men

research The Effect of St. John's Wort on the Pharmacokinetics, Metabolism, and Biliary Excretion of Finasteride and Its Metabolites in Healthy Men

33 citations , November 2008 in “European Journal of Pharmaceutical Sciences”

This study found that St. John's wort treatment for two weeks induced finasteride metabolism and reduced its plasma exposure in healthy men.

research In Vivo Time-Dependent Inhibition of Human Steroid 5α-Reductase by Finasteride

29 citations , January 1996 in “Journal of Pharmaceutical Sciences”

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

research Clinical Pharmacokinetics and Pharmacodynamics of Finasteride

93 citations , January 1996 in “Clinical Pharmacokinectics”

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

Picogram Determination of Finasteride in Human Plasma and Semen by High-Performance Liquid Chromatography with Atmospheric-Pressure Chemical-Ionization Tandem Mass Spectrometry

research Picogram Determination of Finasteride in Human Plasma and Semen by High-Performance Liquid Chromatography with Atmospheric-Pressure Chemical-Ionization Tandem Mass Spectrometry

45 citations , August 1994 in “Journal of Chromatography B: Biomedical Sciences and Applications”

Method detects finasteride in plasma and semen with high sensitivity and accuracy.

research Finasteride: The First 5α-Reductase Inhibitor

23 citations , July 1993 in “Pharmacotherapy”

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

research Finasteride: A Slow-Binding 5-Alpha-Reductase Inhibitor

70 citations , June 1993 in “Biochemistry”

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1040 citations , October 1992 in “The New England Journal of Medicine”

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.